Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: To assess the long‐term glycaemic durability, safety and tolerability of dapagliflozin versus glipizide as add‐on therapies in patients with type 2 diabetes inadequately controlled by metformin alone. Methods: This was a 52‐week, randomised, double‐blind study of dapagliflozin (n = 406) versus glipizide (n = 408), uptitrated over 18 weeks according to tolerability and glycaemic response to a maximum of 10 and 20 mg/day, respectively, as add‐on therapies to metformin (≥1500 mg/day) with a 156‐week double‐blind extension period. Data over 104 weeks are reported here. Results: In total, 53.1% of patients completed 104 weeks of treatment. After the greater initial decrease (0–18 weeks) in glycated haemoglobin ( HbA1c ) with glipizide, the 18–104‐week HbA1c coefficient of failure ( CoF ) was lower with dapagliflozin (0.13%/year) than with glipizide (0.59%/year), resulting in significant dapagliflozin versus glipizide differences of −0.46%/year (95% CI −0.60,−0.33; p = 0.0001) for CoF and −0.18%(−2.0 mmol/mol) [95% CI −0.33(−3.6),−0.03(−0.3); p = 0.021] for 104‐week HbA1c . Dapagliflozin produced sustained reductions in weight and systolic blood pressure, whereas glipizide increased weight and systolic blood pressure, giving 104‐week dapagliflozin versus glipizide differences of −5.1 kg (95% CI : −5.7,−4.4) and −3.9 mmHg (95% CI : −6.1,−1.7), respectively. Over 104 weeks, the hypoglycaemia rate was 10‐fold lower with dapagliflozin than with glipizide (4.2 vs. 45.8%), whereas patient proportions with events suggestive of genital infection and of urinary tract infection ( UTI ) were greater with dapagliflozin (14.8 and 13.5%, respectively) than with glipizide (2.9 and 9.1%, respectively). Conclusions: Over 2 years, compared with glipizide, dapagliflozin demonstrated greater glycaemic durability, sustained reductions in weight and systolic blood pressure and a low hypoglycaemia rate; however, genital infections and UTIs occurred more frequently.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“The lack of durable glycaemic efficacy, weight gain and hypoglycaemic risk associated with sulfonylurea therapy may explain why sulfonylureas are being used less today than in previous decades [27]; however, their low generic cost, together with trial data attesting to some long-term benefits [28,29], contributes to t…”
BackgroundGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“The lack of durable glycaemic efficacy, weight gain and hypoglycaemic risk associated with sulfonylurea therapy may explain why sulfonylureas are being used less today than in previous decades [27]; however, their low generic cost, together with trial data attesting to some long-term benefits [28,29], contributes to t…”
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 1×
“In addition, glucosuria-related caloric loss and osmotic diuresis are associated with weight loss [15] and reduced blood pressure [16].”
BackgroundSelf-citationMeng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634 · cited 3×
“As has been noted with the SGLT2-inhibitor class [15,17,31–38], events suggestive of genital infections and of UTIs, which included non-specific symptoms as well as clinically diagnosed infections, were more frequent with dapagliflozin compared with glipizide and were more commonly reported in women.”
BackgroundKomoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396 · cited 1×
“Dapagliflozin, a highly selective inhibitor of renal sodium-glucose cotransporter 2 (SGLT2) [10,11], lowers blood glucose in patients with type 2 diabetes [12] by reducing renal glucose reabsorption and increasing urinary glucose excretion in a manner dependent on blood glucose level and glomerular filtration rate [13…”
Background
Cited by
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Emerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342
Metadata
- Authors
- Nauck, M. A., Del Prato, S., Durán‐García, S., Rohwedder, K., Langkilde, A. M., Sugg, J., & Parikh, S. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-07-10
- Volume
- 16
- Issue
- 11
- Pages
- 1111-1120
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2065946881
- Cited by
- 113
- References
- 6
- FWCI
- 13.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. https://app.cochat.ai/papers/10.1111/dom.12327
- The paper
- Nauck, M. A., Del Prato, S., Durán‐García, S., Rohwedder, K., Langkilde, A. M., Sugg, J., & Parikh, S. J. (2014). Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12327
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.